Reparixin

Generic Name: Reparixin

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₂₁NO_₃S

CAS Number: 266359-83-5

Unique Ingredient Identifier: U604E1NB3K

Background: Reparixin has been used in trials studying the treatment and prevention of Breast Cancer, Metastatic Breast Cancer, Pancreatectomy for Chronic Pancreatitis, Islet Transplantation in Diabetes Mellitus Type 1, and Pancreatic Islet Transplantation in Type 1 Diabetes Mellitus.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Reparixin in Patients with Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)

Phase 2

Recruiting

Conditions: Myelofibrosis (PMF)
Post Essential Thrombocythemia Myelofibrosis (ET-MF)
Post Polycythemia Vera Related Myelofibrosis (PV-MF)

Interventions: Drug: reparixin

First Posted Date: 2023-04-28

Last Posted Date: 2024-12-02

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 26

Registration Number: NCT05835466

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
Wake Forest Baptist Health Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
🇺🇸
Ruttenberg Treatment Center, New York, New York, United States

Reparixin add-on Therapy to Std Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia

Phase 3

Terminated

Conditions: Severe COVID-19
Infectious Pneumonia

Interventions: Other: Placebo
Drug: Reparixin

First Posted Date: 2022-02-24

Last Posted Date: 2024-10-24

Lead Sponsor: Dompé Farmaceutici S.p.A

Target Recruit Count: 409

Registration Number: NCT05254990

Locations: 🇮🇹
Azienda Ospedaliera Universitaria Arcispedale Sant'Anna, Ferrara, Italy
🇮🇹
Azienda Ospedaliera Universitaria Federico II., Napoli, Italy
🇮🇹
Università degli Studi della Campania "Luigi Vanvitelli", Napoli, Italy

and more 98 locations

To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer

Phase 2

Withdrawn

Conditions: Fatigue
Locally Advanced or Metastatic Breast Cancer

Interventions: Drug: Placebo
Drug: Reparixin

First Posted Date: 2022-01-28

Last Posted Date: 2024-04-30

Lead Sponsor: Dompé Farmaceutici S.p.A

Registration Number: NCT05212701

Locations: 🇮🇹
IRCCS Oncologico Istituto Tumori Giovanni Paolo II, Bari, Italy
🇮🇹
Azienda Ospedaliera di Perugia, Ospedale Santa Maria della Misericordia, Perugia, Italy
🇮🇹
Ospedale Giuseppe Mazzini di Teramo, Teramo, Italy

and more 17 locations

Study on Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia.

Phase 3

Completed

Conditions: Pneumonia, Viral

Interventions: Other: Placebo
Drug: Reparixin

First Posted Date: 2021-05-07

Last Posted Date: 2024-06-13

Lead Sponsor: Dompé Farmaceutici S.p.A

Target Recruit Count: 287

Registration Number: NCT04878055

Locations: 🇺🇸
Franciscan Alliance, 421 N Emerson Ave,, Greenwood, Indiana, United States
🇮🇹
Policlinico S. Orsola Malpighi UO di Pneumologia e Terapia Int. Respiratoria, Bologna, Italy
🇮🇹
Ospedale Policlinico San Martino Malattie infettive e tropicali, Genova, Italy

and more 14 locations

Reparixin in COVID-19 Pneumonia - Efficacy and Safety

Phase 2

Terminated

Conditions: Severe Pneumonia

Interventions: Drug: Standard of care
Drug: Reparixin

First Posted Date: 2021-03-12

Last Posted Date: 2024-01-08

Lead Sponsor: Dompé Farmaceutici S.p.A

Target Recruit Count: 56

Registration Number: NCT04794803

Locations: 🇧🇷
Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina de São Paulo, São Paulo, Brazil
🇮🇹
Ospedale di Varese, Varese, Lombardy, Italy
🇮🇹
Ospedale San Paolo, Milan, Lombardy, Italy

and more 1 locations

Pilot Study of Reparixin for Early Allograft Dysfunction Prevention in Liver Transplantation

Phase 2

Terminated

Conditions: Ischemia-reperfusion Injury in Liver Transplant
Early Allograft Dysfunction

Interventions: Drug: Reparixin
Other: Control

First Posted Date: 2017-01-25

Last Posted Date: 2024-12-11

Lead Sponsor: Dompé Farmaceutici S.p.A

Target Recruit Count: 40

Registration Number: NCT03031470

Locations: 🇧🇾
Healthcare Organization "9th City Clinical Hospital", Minsk, Belarus
🇷🇺
State Budgetary Educational Institution of Higher Professional Education "First Saint Petersburg State Medical University n.a. I.P. Pavlov" of the Ministry of Health of the Russian Federation, St. Petersburg, Saint Petersburg, Russian Federation
🇷🇺
State Budgetary Health Institution of Novosibirsk Region "State Novosibirsk Regional Clinical Hospital", Novosibirsk, Russian Federation

and more 4 locations

A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer

Phase 2

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: paclitaxel
Drug: placebo
Drug: Reparixin

First Posted Date: 2015-02-24

Last Posted Date: 2022-09-16

Lead Sponsor: Dompé Farmaceutici S.p.A

Target Recruit Count: 194

Registration Number: NCT02370238

Locations: 🇧🇪
AZ St Elisabeth, Namur, Belgium
🇺🇸
Southeastern Regional Medical Center, Newnan, Georgia, United States
🇺🇸
Regional Cancer Care Associates, Sparta, New Jersey, United States

and more 63 locations

Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation

Phase 2

Completed

Conditions: Pancreatectomy for Chronic Pancreatitis

Interventions: Drug: Placebo
Drug: Reparixin

First Posted Date: 2013-10-23

Last Posted Date: 2023-11-02

Lead Sponsor: Dompé Farmaceutici S.p.A

Target Recruit Count: 104

Registration Number: NCT01967888

Locations: 🇺🇸
Thomas E. Starzl Transplantation Institute University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸
Baylor University Medical Center, Dallas, Texas, United States
🇺🇸
University of California. Department of Surgery, Division of Transplantation, San Francisco, California, United States

and more 6 locations

Pilot Study to Evaluate Safety & Biological Effects of Orally Administered Reparixin in Early Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: Reparixin

First Posted Date: 2013-05-23

Last Posted Date: 2021-05-14

Lead Sponsor: Dompé Farmaceutici S.p.A

Target Recruit Count: 20

Registration Number: NCT01861054

Locations: 🇺🇸
The Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
Weill Cornell Medical College, New York, New York, United States
🇺🇸
Montefiore Medical Center, MMC Medical Park at Eastchester, Bronx, New York, United States

and more 6 locations

Study to Assess Efficacy & Safety of Reparixin in Pancreatic Islet Transplantation

Phase 3

Completed

Conditions: Islet Transplantation in Diabetes Mellitus Type 1

Interventions: Drug: Reparixin
Drug: Placebo

First Posted Date: 2013-03-26

Last Posted Date: 2024-01-03

Lead Sponsor: Dompé Farmaceutici S.p.A

Target Recruit Count: 51

Registration Number: NCT01817959

Locations: 🇮🇹
Dipartimento di Medicina Interna e Specialistica; IRCCS Ospedale San Raffaele, Milan, Italy
🇮🇹
S.S.D. Diabetologia, Azienda Ospedaliera Ospedale Niguarda Ca' Granda, Piazza Ospedale Maggiore 3, Milan, Italy
🇨🇿
Institute for Clinical and Experimental Medicine (IKEM), Diabetes Centre; Department of Diabetes., Praha, Czechia

and more 6 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy